FDA approves nuzyra for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adults
The FDA has approved nuzyra for the treatment of community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections in adult patients. This decision follows a regulatory approval process rather than a published clinical trial report within this specific text. The sample size for the underlying data was not reported, and the setting was not reported. No comparator was reported in the provided text. The primary outcome was not reported, and secondary outcomes were not reported. The follow-up duration was not reported. Adverse events were not reported, serious adverse events were not reported, discontinuations were not reported, and tolerability was not reported. Funding or conflicts of interest were not reported. Limitations were not reported. Practice relevance was not reported. The certainty note states that FDA approval indicates regulatory clearance based on submitted data; specific efficacy and safety data are not reported in this text.
＋ Clinical Details (Mechanism · Dosing · Trial Data · Warnings)
Omadacycline is a tetracycline class antibacterial. It acts by inhibiting bacterial protein synthesis by binding to the 30S ribosomal subunit. The specific mechanism is not further detailed in the label.
Nuzyra is indicated for the treatment of adult patients with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms: Streptococcus pneumoniae, Staphylococcus aureus (methicillin-susceptible isolates), Haemophilus influenzae, Haemophilus parainfluenzae, Klebsiella pneumoniae, Legionella pneumophila, Mycoplasma pneumoniae, and Chlamydophila pneumoniae. It is also indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible microorganisms: Staphylococcus aureus (methicillin-susceptible and -resistant isolates), Staphylococcus lugdunensis, Streptococcus pyogenes, Streptococcus anginosus grp. (includes S. anginosus, S. intermedius, and S. constellatus), Enterococcus faecalis, Enterobacter cloacae, and Klebsiella pneumoniae.
For CABP, the recommended dosage is: Day 1 loading dose: either 200 mg IV infusion over 60 minutes or 100 mg IV infusion over 30 minutes twice, OR 300 mg orally twice. Maintenance dose: 100 mg IV infusion over 30 minutes once daily OR 300 mg orally once daily. For ABSSSI, the recommended dosage is: Day 1 loading dose: either 200 mg IV infusion over 60 minutes or 100 mg IV infusion over 30 minutes twice, OR 450 mg orally once daily on Day 1 and Day 2. Maintenance dose: 100 mg IV infusion over 30 minutes once daily OR 300 mg orally once daily. Treatment duration is 7 to 14 days. Important administration instructions: For oral tablets, fast for at least 4 hours, then take with water. After oral dosing, no food or drink (except water) for 2 hours, and no dairy products, antacids, or multivitamins for 4 hours. For IV, do not administer with any solution containing multivalent cations (e.g., calcium, magnesium) through the same IV line. No dosage adjustment is needed for renal or hepatic impairment.
Trial data not available in label.
Not reported in label.
Nuzyra provides an additional option for empiric treatment of CABP and ABSSSI in adults, particularly when oral therapy is desired. Its spectrum includes typical and atypical respiratory pathogens and key skin pathogens including MRSA. However, the significant food and drug interactions may limit convenience. Use should be guided by susceptibility data when available.
View Original Abstract ↓
Intrawound tobramycin plus vancomycin did not reduce deep infection risk compared with vancomycin alone in high-risk tibial fractures
Adding Antibiotics to Bone Surgery Didn't Lower Infection Risk
Related in Infectious Disease
From Other Specialties
